Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian M Olson

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
Cancer Immunology, Immunotherapy : CII|October 31, 2012
The androgen receptor: a biologically relevant vaccine target for the treatment of prostate cancerBrian M Olson, Laura E Johnson, Douglas G McNeel
Current Cancer Therapy Reviews|March 4, 2014
DNA Vaccines for Prostate CancerDouglas G McNeel, Jordan T Becker, Laura E Johnson, et al.
Urologic Oncology|December 17, 2013
Preclinical and clinical development of DNA vaccines for prostate cancerV T Colluru, Laura E Johnson, Brian M Olson, et al.
Protein Expression and Purification|September 10, 2003
A cross-reactive polyol-responsive monoclonal antibody useful for isolation of core RNA polymerase from many bacterial speciesVeit Bergendahl, Nancy E Thompson, Kit M Foley, et al.
Cancer Immunology Research|June 5, 2015
PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine ImmunizationBrian T Rekoske, Heath A Smith, Brian M Olson, et al.
Frontiers in Immunology|September 28, 2020
Infectious Tolerance as Seen With 2020 Vision: The Role of IL-35 and Extracellular VesiclesJeremy A Sullivan, David P AlAdra, Brian M Olson, et al.
Chinese Clinical Oncology|December 11, 2013
Prostate carcinoma in transgenic Lewis rats - a tumor model for evaluation of immunological treatmentsLaura E Johnson, Jordan T Becker, Jason A Dubovsky, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 17, 2010
DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancerJordan T Becker, Brian M Olson, Laura E Johnson, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 16, 2012
Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockadeBrian M Olson, Ewa Jankowska-Gan, Jordan T Becker, et al.
Cancer Immunology, Immunotherapy : CII|February 9, 2010
HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphataseBrian M Olson, Thomas P Frye, Laura E Johnson, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Cancer Immunology, Immunotherapy : CII|October 31, 2012
The androgen receptor: a biologically relevant vaccine target for the treatment of prostate cancerBrian M Olson, Laura E Johnson, Douglas G McNeel
Current Cancer Therapy Reviews|March 4, 2014
DNA Vaccines for Prostate CancerDouglas G McNeel, Jordan T Becker, Laura E Johnson, et al.
Urologic Oncology|December 17, 2013
Preclinical and clinical development of DNA vaccines for prostate cancerV T Colluru, Laura E Johnson, Brian M Olson, et al.
Protein Expression and Purification|September 10, 2003
A cross-reactive polyol-responsive monoclonal antibody useful for isolation of core RNA polymerase from many bacterial speciesVeit Bergendahl, Nancy E Thompson, Kit M Foley, et al.
Cancer Immunology Research|June 5, 2015
PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine ImmunizationBrian T Rekoske, Heath A Smith, Brian M Olson, et al.
Frontiers in Immunology|September 28, 2020
Infectious Tolerance as Seen With 2020 Vision: The Role of IL-35 and Extracellular VesiclesJeremy A Sullivan, David P AlAdra, Brian M Olson, et al.
Chinese Clinical Oncology|December 11, 2013
Prostate carcinoma in transgenic Lewis rats - a tumor model for evaluation of immunological treatmentsLaura E Johnson, Jordan T Becker, Jason A Dubovsky, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 17, 2010
DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancerJordan T Becker, Brian M Olson, Laura E Johnson, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 16, 2012
Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockadeBrian M Olson, Ewa Jankowska-Gan, Jordan T Becker, et al.
Cancer Immunology, Immunotherapy : CII|February 9, 2010
HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphataseBrian M Olson, Thomas P Frye, Laura E Johnson, et al.
Pageof 3